Judith Jaeger is neuropsychologist and pharmaceutical executive with more than 30 years’ experience in clinical and experimental neuropsychology and psychopathology. She is Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine, New York as well as President and Principal Scientist at CognitionMetrics, LLC in Wilmington, Delaware, USA. Previously she was Vice President for Clinical Trials at Cogstate, Inc. and Director of Clinical Development at AstraZeneca Pharmaceuticals where she served as company-wide cognition expert for programs in Alzheimer’s disease, ADHD, schizophrenia, bipolar disorder and oncology. Prof. Jaeger’s pharmaceutical industry work has included Phase 0 experimental medicine studies that she has initiated, as well as innovative (Phase Ib/IIa) and conventional (Phase II) PoP/PoC studies as well as pivotal (Phase III) and post-marketing studies. Her global regulatory experience includes speaking before regulatory bodies including the PMDA (Japanese regulatory authories) and with FDA including at an Advisory Committee. She has consulted to clinical teams in 15 of the top 25 pharmaceutical companies in all phases of development on a range of CNS and non-CNS (safety) indications. Professor Jaeger is known for her research on measurement of cognition across a range of central nervous system diseases, with particular attention to measurement of change over time in clinical trials. She has also studied cognitive impairments and their association with disability in psychiatric disorders, including schizophrenia, bipolar and major depressive disorder. She has over 70 peer-reviewed publications, one edited book, seven book chapters and more than 200 published abstracts, conference presentations and invited lectures.